Jade Biosciences (JBIO) Operating Expenses (2020 - 2026)

Jade Biosciences has reported Operating Expenses for 7 years, with the latest figure at $43.4 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 85.79% year-over-year to $43.4 million; the trailing twelve-month figure through Mar 2026 stood at $133.6 million (up 79.39% YoY), and the FY2025 full-year result was $113.5 million, up 52.21% from the prior year.
• Operating Expenses for Q1 2026 stood at $43.4 million, up from $35.0 million in the prior quarter.
• The five-year high for Operating Expenses was $43.4 million in Q1 2026, with the low at $590000.0 in Q2 2024.
• Historically, Operating Expenses has averaged $21.6 million across 5 years, with a median of $21.4 million in 2023.
• Annual changes were most pronounced in 2024 — Operating Expenses tumbled 97.1% — and 2025, when it soared 4608.14%.
• Jade Biosciences' Operating Expenses stood at $15.9 million in 2022, then surged by 39.2% to $22.1 million in 2023, then jumped by 61.05% to $35.5 million in 2024, then slipped by 1.57% to $35.0 million in 2025, then rose by 24.2% to $43.4 million in 2026.
• The last three Operating Expenses figures came in at $43.4 million (Q1 2026), $35.0 million (Q4 2025), and $27.4 million (Q3 2025), per Business Quant data.